Biotech Values

[iwfal]

GERN -

However, concerns over an ongoing investigation into lab value abnormalities from its essential thrombocythemia study, plus opaque visibility on imetelstat progress have prompted a number of firms to cut their ratings.

The opacity has, of course, been my primary concern over GERN. As usual opacity is an indicator of future problems. (Right now there is only one biotech I would trust if they were opaque on a significant subject. Trust is something hard earned and easily squandered.)